PubRank

Christopher C Benz

Author PubWeight™ 95.69‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Integrated genomic characterization of endometrial carcinoma. Nature 2013 14.29
2 Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006 5.47
3 Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2006 4.59
4 Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006 4.43
5 Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005 3.66
6 Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009 3.40
7 Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002 3.14
8 Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006 2.83
9 Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 2008 2.12
10 Breast cancer growth prevention by statins. Cancer Res 2006 2.09
11 First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants. Cancer Causes Control 2014 2.05
12 Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007 1.57
13 A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 2010 1.50
14 Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 2004 1.48
15 Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004 1.45
16 Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat 2011 1.39
17 Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 2008 1.32
18 Targeted quantitation of site-specific cysteine oxidation in endogenous proteins using a differential alkylation and multiple reaction monitoring mass spectrometry approach. Mol Cell Proteomics 2010 1.26
19 ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res 2010 1.24
20 Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 2005 1.23
21 Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 2009 1.23
22 Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 2007 1.22
23 Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res 2011 1.20
24 Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res 2007 1.17
25 Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res 2007 1.15
26 Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res 2008 1.11
27 Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Mol Cell Proteomics 2008 1.11
28 Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002 1.08
29 Age-dependent changes in breast cancer hormone receptors and oxidant stress markers. Breast Cancer Res Treat 2002 1.05
30 Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol 2007 1.04
31 Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res 2005 1.03
32 A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol 2006 0.99
33 Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol Cancer Ther 2002 0.99
34 Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers. Breast Cancer Res 2008 0.98
35 Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 2002 0.98
36 Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol 2009 0.95
37 ErbB2 activation of ESX gene expression. Oncogene 2002 0.94
38 Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers. Breast Cancer Res Treat 2011 0.93
39 Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release 2009 0.92
40 A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells. J Am Soc Mass Spectrom 2008 0.90
41 Redox control of zinc finger proteins. Methods Enzymol 2002 0.89
42 655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations. Cell Oncol 2007 0.87
43 FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat 2013 0.87
44 Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma. Mol Cell Proteomics 2014 0.87
45 Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. Assay Drug Dev Technol 2006 0.86
46 Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells? Breast Cancer Res Treat 2012 0.86
47 Reactivity of zinc finger cysteines: chemical modifications within labile zinc fingers in estrogen receptor. J Am Soc Mass Spectrom 2005 0.85
48 Essential cysteine-alkylation strategies to monitor structurally altered estrogen receptor as found in oxidant-stressed breast cancers. Anal Biochem 2003 0.85
49 An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast Cancer Res 2013 0.85
50 Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305. Mol Cancer Res 2012 0.83
51 Label-Free Quantitation and Mapping of the ErbB2 Tumor Receptor by Multiple Protease Digestion with Data-Dependent (MS1) and Data-Independent (MS2) Acquisitions. Int J Proteomics 2013 0.81
52 Quantification of cysteine oxidation in human estrogen receptor by mass spectrometry. Anal Chem 2007 0.81
53 Risk factors for estrogen receptor-positive breast cancer. Arch Surg 2005 0.80
54 Hyperplasia, reduced E-cadherin expression, and developmental arrest in mammary glands oxidatively stressed by loss of mitochondrial superoxide dismutase. Breast 2005 0.80
55 Age-related micro-RNA abundance in individual C. elegans. Aging (Albany NY) 2013 0.79
56 Vitamin K3 (menadione)-induced oncosis associated with keratin 8 phosphorylation and histone H3 arylation. Mol Pharmacol 2005 0.79
57 Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol 2006 0.77
58 Clinical trials are required to prove the chemopreventive worth of statins. Arch Intern Med 2006 0.75
59 Identification of an epithelial-specific enhancer regulating ESX expression. Gene 2005 0.75